stockrow
Friday 6 November 2026
Export ICUI’s income statement to Excel — free account
ICU Medical, Inc.
ICUI Healthcare Medical Instruments & Supplies
ICU Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, down 6.33% from fiscal 2024.
- Revenue
- +4.37%
- EPS
- +864.3%
- Free cash flow
- +292.2%
- Total debt
- −12.3%
Quarter to September 2026, against a year earlier
172.03
4.38
+2.61%
Follow ICUI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
7,133.50 | 69.06 | 122.17 | 66.60 |
P/S ratio |
1.58 | 1.48 | 1.70 | 1.84 | |
P/FCF ratio |
38.68 | 38.97 | 23.97 | 20.40 | |
P/Operating CF |
58.01 | 82.20 | 45.73 | 40.31 | |
P/B ratio |
1.66 | 1.51 | 1.70 | 1.83 | |
Price to Tangible BV |
0.00 | 116.73 | 36.72 | 23.31 | |
EV/Sales |
2.01 | 1.94 | 2.13 | 2.23 | |
EV/EBITDA |
17.99 | 16.76 | 16.56 | 15.48 | |
EV/Operating CF |
24.98 | 25.03 | 19.45 | 17.42 | |
EV/FCF |
49.42 | 51.06 | 30.07 | 24.72 | |
Quick Ratio |
0.98 | 0.95 | 0.97 | 0.99 | |
Current Ratio |
2.39 | 2.34 | 2.43 | 2.37 | |
Net Debt/EBITDA |
16.98 | 15.41 | 10.42 | 8.27 | |
Debt/Assets |
31.72% | 31.90% | 31.00% | 29.21% | |
Debt/Equity |
0.60 | 0.61 | 0.57 | 0.53 | |
Asset Turnover |
0.54 | 0.53 | 0.53 | 0.54 | |
Operating CF/Net income |
(3.85) | 1.29 | 4.20 | 3.71 | |
Capex/Depreciation |
(0.35) | (0.26) | (0.40) | (0.03) | |
Interest Coverage |
0.27 | 0.82 | 2.48 | — | |
Research and Development Expense of Revenue |
3.90% | 4.01% | 4.12% | 3.88% | |
Selling, General and Administrative Expense of Revenue |
28.82% | 29.15% | 27.54% | 27.55% | |
Intangible Assets out of Total Assets |
0.53 | 0.52 | 0.52 | 0.51 | |
Share Based Compensation of Revenue |
2.57% | 2.64% | 2.15% | 2.12% | |
Graham Net Nets |
(0.21) | (0.22) | (0.17) | (0.13) | |
Graham Number |
6.23 | 59.90 | 48.21 | 68.93 | |
Earnings Yield |
0.01% | 1.45% | 0.82% | 1.50% | |
Free Cash Flow Yield |
2.59% | 2.57% | 4.17% | 4.90% | |
Revenue per Share |
21.94 | 21.41 | 22.07 | 22.41 | |
Operating CF per Share |
2.46 | 1.57 | 3.21 | 3.98 | |
Capex per Share |
(0.75) | (0.53) | (0.81) | (0.07) | |
Free Cash Flow per Share |
1.71 | 1.04 | 2.40 | 3.91 | |
Cash per Share |
12.50 | 11.64 | 11.93 | 12.07 | |
Shareholders Equity per Share |
86.19 | 85.28 | 86.07 | 87.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
86.19 | 85.28 | 86.07 | 87.63 | |
Free Cash Flow |
42.21 | 25.70 | 60.01 | 97.90 | |
Working Capital |
691.69 | 695.34 | 712.54 | 705.23 | |
Capital Expenditures |
(18.39) | (13.21) | (20.14) | (1.69) | |
Net Current Asset Value |
(736.13) | (688.59) | (608.52) | (532.52) | |
EV/EBIT |
104.88 | 96.29 | 63.81 | 43.95 | |
Capex to Sales |
0.03 | 0.02 | 0.04 | 0.00 | |
Price to Operating Income |
82.08 | 73.49 | 50.86 | 36.27 | |
| Other line items | |||||
Average Receivables |
181.67 | 186.00 | 181.51 | 198.90 | |
Average Payables |
151.20 | 177.20 | 158.99 | 157.37 | |
Average Inventory |
600.27 | 597.96 | 611.95 | 614.86 | |
Average Assets |
4,127.22 | 4,099.17 | 4,039.34 | 4,023.35 | |
Average Common Equity |
2,044.53 | 2,049.81 | 2,133.81 | 2,159.33 |
Columns are period end dates · fundamentals updated 5 Nov 2026